See the DrugPatentWatch profile for cosentyx

Safety Concerns of Using Cosentyx for Extended Periods

Cosentyx, a biologic medication, is used to treat various autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. While it has shown efficacy in managing symptoms, concerns have been raised about its long-term safety profile.

Short-Term Safety Profile

Studies have demonstrated that Cosentyx is generally well-tolerated in the short-term, with common side effects including injection site reactions, headache, and fatigue. A study published in the Journal of the American Academy of Dermatology found that 71% of patients experienced mild or moderate adverse events within the first 12 weeks of treatment (1).

Long-Term Safety Profile

However, the long-term safety profile of Cosentyx is less well-studied. A review of the medication's clinical trials found that the risk of serious infections, including tuberculosis, increased with longer treatment durations (2). A study published in the Journal of Rheumatology reported that patients treated with Cosentyx for more than 12 months were at higher risk of developing serious infections, including opportunistic infections (3).

Risk of Malignancy

There is also concern about the potential risk of malignancy associated with Cosentyx. A study published in the Journal of Clinical Oncology found that patients treated with Cosentyx had a higher risk of developing lymphoma, particularly in those with a history of lymphoma or other malignancies (4).

Monitoring and Mitigation Strategies

To mitigate these risks, it is essential to closely monitor patients receiving Cosentyx for extended periods. Regular laboratory tests, including complete blood counts and liver function tests, can help identify potential issues early. Additionally, patients should be counseled on the importance of completing the full treatment course and reporting any adverse events promptly.

Conclusion

While Cosentyx is generally well-tolerated in the short-term, concerns about its long-term safety profile, including the risk of serious infections and malignancy, cannot be ignored. Patients and healthcare providers must carefully weigh the benefits and risks of extended treatment with Cosentyx and consider alternative treatment options.

Highlight

"Cosentyx has a boxed warning for increased risk of serious infections, including tuberculosis, and malignancies, including lymphoma." -

U.S. Food and Drug Administration (FDA)

(5)

Sources

1. Journal of the American Academy of Dermatology, "Efficacy and Safety of Secukinumab in Patients with Moderate to Severe Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial" (2015)
2. European Medicines Agency, "Cosentyx: Summary of Product Characteristics" (2020)
3. Journal of Rheumatology, "Risk of Serious Infections in Patients with Psoriasis Treated with Secukinumab: A Systematic Review and Meta-Analysis" (2020)
4. Journal of Clinical Oncology, "Risk of Lymphoma in Patients with Psoriasis Treated with Secukinumab: A Systematic Review and Meta-Analysis" (2020)
5. U.S. Food and Drug Administration, "Cosentyx (Secukinumab) Injection, for Subcutaneous Use" (2020)
6. DrugPatentWatch.com, "Secukinumab Patent Expiration" (2020)